Contineum Therapeutics Inc. Class A Common Stock (CTNM)
Stock · NASDAQ · Health Care
$7.07as of 10/16/2026
Price chart
Active signals
CTNM Signal Track Record
How signals performed across all stocks →What CTNM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 18 | -2.7% | 44% | September 30, 2026 |
| Bollinger Band Breakout | 8 | -10.4% | 25% | August 21, 2026 |
| Bollinger Band BreakdownActive now | 6 | +14.2% | 67% | September 15, 2026 |
| Any 20-session window (baseline) | +0.5% | 51% |
Computed by MarketWall from daily closing prices since January 22, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 51
- Website
- www.contineum-tx.com/
Fundamentals
- 1-day range
- $7.73$8.56
- Market cap
- $577.48M
- P/E (trailing)
- —
- P/E (forward)
- -4.10
- EPS (trailing)
- $-1.74
- Dividend yield
- —
- Beta
- 0.95
- Avg. volume
- 705.4K
Forecasts
7 analyst ratings
Contineum Therapeutics Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.08$6.13$13.02
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.08 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesdaybenzinga · 10/14/2026
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsYahoo · 9/30/2026
- Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On WednesdayBenzinga · 9/30/2026
- Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17Benzinga · 9/28/2026
- J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?Yahoo · 9/24/2026
- Sector Update: Healthcare Stocks Ease Late AfternoonYahoo · 9/15/2026
- FDA clears first generic radioligand drug; Sionna turns to layoffsYahoo · 9/15/2026
- Johnson & Johnson Partner Contineum Slides as Depression Drug FailsYahoo · 9/15/2026
- Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19Benzinga · 9/15/2026
Insider Activity
Insider Actions →- Carmine N. Stengone · September 8, 2026 · Option Exercise2.5K @ $1.01
- Carmine N. Stengone · September 8, 2026 · Sale2.5K @ $16.46
- Carmine N. Stengone · August 3, 2026 · Option Exercise2.5K @ $1.01
- Carmine N. Stengone · August 3, 2026 · Sale2.5K @ $16.01
- Daniel S. Lorrain · July 9, 2026 · Option Exercise25 @ $1.01
- Daniel S. Lorrain · July 9, 2026 · Sale25 @ $16
- Daniel S. Lorrain · July 8, 2026 · Option Exercise1.0K @ $1.01
- Daniel S. Lorrain · July 8, 2026 · Sale1.0K @ $16
- Carmine N. Stengone · July 8, 2026 · Option Exercise2.5K @ $1.01
- Carmine N. Stengone · July 8, 2026 · Sale2.5K @ $16
- Daniel S. Lorrain · July 1, 2026 · Option Exercise4.2K @ $1.01
- Daniel S. Lorrain · July 1, 2026 · Sale2.5K @ $16.24
- Daniel S. Lorrain · July 1, 2026 · Sale5.9K @ $15.67
- Daniel S. Lorrain · June 30, 2026 · Sale28.8K @ $16.04
- Tim Watkins · June 30, 2026 · Option Exercise10.8K @ $4.5
Institutional Ownership
March 31, 2026
- Total shares held
- 30.39M
- Total value held
- $395.60M
- Institutional holders
- 86
- Unknown2.84M
- Unknown2.73M
- Unknown1.98M
- Unknown1.84M
- Unknown1.69M
- Unknown1.54M
- Unknown1.42M
- Unknown1.30M
- Unknown1.26M
- Unknown1.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
CTNM Depressed After Phase 2 Miss
Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.
CTNM Depressed After Phase 2 Miss. Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.